Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 25

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 25
---
000037 |     | 11-Sep-24 |     | Section 8 & 15 Due                         |
| United States of America  |     | ARAKODA                |     | Registered |     |     87688137 |     | 16-Nov-17  |     | 12/31/2019   |     |             5950691 |     | 0081716-000050 |     | 31-Dec-25 |     | Section 8 & 15 Due                         |
| United States of America  |     | KODATEF                |     | Abandoned- |     |     90072885 |     | 24-Jul-20  |     |              |     |                     |     | 0081716-000069 |     | 16-Aug-23 |     | Statement of Use/3rd Extension of Time Due |
| United  States of America |     | KODATEF                |     | Allowed    |     |   98/363,219 |     | 18-Jan-24  |     |              |     |                     |     | 0081716-000074 |     | 12-May-25 |     | Statement of Use/1st Extension of Time Due |

Key Relationships & Licenses On May 30, 2014, we entered into the Exclusive License Agreement (the “2014 NUS-SHS Agreement”) with National University of Singapore (“NUS”) and Singapore Health Services Pte Ltd (“SHS”) in which we were granted a license from NUS and SHS with respect to their share of patent rights regarding “Dosing Regimen for Use of Celgosivir as an Antiviral Therapeutic for Dengue Virus Infection” to develop, market and sell licensed products. The 2014 NUS-SHS Agreement continues in force until the expiration of the last to expire of any patents under the patent rights unless terminated earlier in accordance with the 2014 NUS-SHS Agreement. We are obligated to pay royalties at the rate of 1.5% of gross sales.

13 On July 15, 2015, we entered into the Exclusive License Agreement with the U.S. Army Medical Materiel Development Activity (the “U.S. Army”), which was subsequently amended (the “U.S. Army Agreement”), in which we obtained a license to develop and commercialize the licensed technology with respect to all therapeutic applications and uses excluding radical cure of symptomatic vivax